Hooper L, Thompson R L, Harrison R A, Summerbell C D, Moore H, Worthington H V, Durrington P N, Ness A R, Capps N E, Davey Smith G, Riemersma R A, Ebrahim S B J
MANDEC, University Dental Hospital of Manchester, Higher Cambridge Street, Manchester, UK, M15 6FH.
Cochrane Database Syst Rev. 2004 Oct 18(4):CD003177. doi: 10.1002/14651858.CD003177.pub2.
It has been suggested that omega 3 (W3, n-3 or omega-3) fats from oily fish and plants are beneficial to health.
To assess whether dietary or supplemental omega 3 fatty acids alter total mortality, cardiovascular events or cancers using both RCT and cohort studies.
Five databases including CENTRAL, MEDLINE and EMBASE were searched to February 2002. No language restrictions were applied. Bibliographies were checked and authors contacted.
RCTs were included where omega 3 intake or advice was randomly allocated and unconfounded, and study duration was at least six months. Cohorts were included where a cohort was followed up for at least six months and omega 3 intake estimated.
Studies were assessed for inclusion, data extracted and quality assessed independently in duplicate. Random effects meta-analysis was performed separately for RCT and cohort data.
Forty eight randomised controlled trials (36,913 participants) and 41 cohort analyses were included. Pooled trial results did not show a reduction in the risk of total mortality or combined cardiovascular events in those taking additional omega 3 fats (with significant statistical heterogeneity). Sensitivity analysis, retaining only studies at low risk of bias, reduced heterogeneity and again suggested no significant effect of omega 3 fats. Restricting analysis to trials increasing fish-based omega 3 fats, or those increasing short chain omega 3s, did not suggest significant effects on mortality or cardiovascular events in either group. Subgroup analysis by dietary advice or supplementation, baseline risk of CVD or omega 3 dose suggested no clear effects of these factors on primary outcomes. Neither RCTs nor cohorts suggested increased relative risk of cancers with higher omega 3 intake but estimates were imprecise so a clinically important effect could not be excluded.
REVIEWERS' CONCLUSIONS: It is not clear that dietary or supplemental omega 3 fats alter total mortality, combined cardiovascular events or cancers in people with, or at high risk of, cardiovascular disease or in the general population. There is no evidence we should advise people to stop taking rich sources of omega 3 fats, but further high quality trials are needed to confirm suggestions of a protective effect of omega 3 fats on cardiovascular health. There is no clear evidence that omega 3 fats differ in effectiveness according to fish or plant sources, dietary or supplemental sources, dose or presence of placebo.
有人提出,来自油性鱼类和植物的ω-3(W3、n-3或欧米伽-3)脂肪酸对健康有益。
通过随机对照试验(RCT)和队列研究,评估膳食或补充ω-3脂肪酸是否会改变总死亡率、心血管事件或癌症发生率。
检索了包括Cochrane系统评价数据库(CENTRAL)、医学索引数据库(MEDLINE)和荷兰医学文摘数据库(EMBASE)在内的五个数据库,检索截至2002年2月。未设语言限制。检查了参考文献并与作者进行了联系。
纳入的RCT需满足ω-3摄入量或相关建议是随机分配且无混杂因素,研究持续时间至少为六个月。纳入的队列研究需满足对队列随访至少六个月并估算了ω-3摄入量。
对研究进行纳入评估,数据提取和质量评估由两人独立重复进行。对RCT和队列数据分别进行随机效应荟萃分析。
纳入了48项随机对照试验(36913名参与者)和41项队列分析。汇总的试验结果未显示额外摄入ω-3脂肪酸的人群总死亡率或合并心血管事件风险降低(存在显著的统计学异质性)。敏感性分析仅保留偏倚风险低的研究,降低了异质性,再次表明ω-3脂肪酸无显著影响。将分析限制在增加鱼类来源ω-3脂肪酸的试验或增加短链ω-3脂肪酸的试验中,两组对死亡率或心血管事件均未显示显著影响。按膳食建议或补充剂、心血管疾病基线风险或ω-3剂量进行亚组分析,这些因素对主要结局均未显示明显影响。RCT和队列研究均未提示ω-3摄入量较高会增加癌症相对风险,但估计值不精确,因此不能排除具有临床重要意义的影响。
尚不清楚膳食或补充ω-3脂肪酸是否会改变心血管疾病患者或高危人群或一般人群的总死亡率、合并心血管事件或癌症发生率。没有证据表明我们应建议人们停止食用富含ω-3脂肪酸的食物,但需要进一步的高质量试验来证实ω-3脂肪酸对心血管健康具有保护作用的观点。没有明确证据表明ω-3脂肪酸在鱼类或植物来源、膳食或补充剂来源、剂量或是否有安慰剂方面的有效性存在差异。